Drug Search Results
More Filters [+]

Ceftazidime

Alternative Names: ceftazidime, fortum, ceftazidim, AVYCAZ, tazicef, ceftazidima, fortaz, ceptaz, fortaz in plastic container, pentacef, tazidime in plastic container, tazidime
Latest Update: 2024-10-04
Latest Update Note: Clinical Trial Update

Product Description

Ceftazidime injection is used to treat bacterial infections in many different parts of the body. It belongs to the class of medicines known as cephalosporin antibiotics. It works by killing bacteria or preventing their growth. However, this medicine will not work for colds, flu, or other virus infections. (Sourced from: https://www.mayoclinic.org/drugs-supplements/ceftazidime-injection-route/side-effects/drg-20073334?p=1)

Mechanisms of Action: PBP Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Approved

Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam

Approved Indications: Urinary Tract Infections | Nephritis | Pyelonephritis

Known Adverse Events: Constipation

Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Ceftazidime

Countries in Clinic: China, Japan, Spain, Thailand

Active Clinical Trial Count: 8

Highest Development Phases

Phase 3: Acute Respiratory Distress Syndrome|Fractures, Open|Pneumonia

Phase 2: Bronchiectasis|Bronchitis, Chronic|Chronic Obstructive Pulmonary Disease|Melioidosis|Pyelonephritis|Respiratory Tract Infections|Urinary Tract Infections

Phase 1: Pneumonia, Ventilator-Associated

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

DURATIOM

P3

Unknown Status

Fractures, Open

2027-12-31

ARV-1801-001

P2

Completed

Melioidosis

2023-10-10

24%

ARV-1801-001

P2

Completed

Melioidosis

2023-10-10

24%

jRCT2061210026

P3

Completed

Unknown

2022-09-15

ASPIC

P3

Active, not recruiting

Pneumonia|Acute Respiratory Distress Syndrome

2021-07-27

Recent News Events